Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia

European Journal of Clinical Investigation

Volumn 36, Issue 8, 2006, Pages 560-565

  Iovine, C ^a   Lilli, S ^a   Gentile, A ^a   Patti, L ^a   Di Marino, L ^a   Cipriano, P ^a   Riccardi, G ^a   Rivellese, A A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atorvastatin; Drugs; Fenofibrate; Post prandial lipaemia; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; ATORVASTATIN; CHYLOMICRON; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENSITY GRADIENT CENTRIFUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICAL SIGNIFICANCE;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROCETOFEN; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33746122627     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01677.x     Document Type: Article

References (27)

1. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140:650-8.
2. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
3. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-9.
4. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil. HA. Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
7. American. Diabetes Association Clinical practice recommendations 2005. Diabetes Care 2005;28:S1-79.
8. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
9. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.
10. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.
11. Teno S, Uto Y, Nagashima H, Endoh Y, Iwamoto Y, Omori Y et al. Association of post-prandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-6.
12. Hyson D, Rutledge JC, Berglund L. Post-prandial lipemia and cardiovascular disease. Curr Atheroscler Rep 2003;5:437-44.
13. Iovine C, Vaccaro O, Gentile A, Romano G, Pisanti F, Riccardi G et al. Post-prandial triglyceride profile in a population-based sample of Type 2 diabetic patients. Diabetologia 2004;47:19-22.
14. Rivellese AA, De Natale C, Di Marino L, Patti L, Iovine C, Coppola S et al. Exogenous and endogenous post-prandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004;89:2153-9.
15. Castro Cabezas M, Verseyden C, Meijssen S, Jansen H, Erkelens DW. Effects of atorvastatin on the clearance of triglyceride-rich lip oproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 2004;89:5972-80.
16. Boquist S, Karpe F, Danell-Toverud K, Hamsten A. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. Atherosclerosis 2002;162:163-70.
17. Guerin M, Egger P, Le Goff W, Soudant C, Dupuis R, Chapman MJ. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol Metab 2002;87:4991-5000.
18. Weintraub MS, Charach G, Grosskopf I. Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis 1998;14:S71-5.
19. Frost RJA, Carsten O, Geiss C, Schwandt Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subftraction distribution, and hemoreologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87:44-8.
20. Westphal S, Wiens L, Guttler K, Dierkes J, Luley C. Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. Atherosclerosis 2003;171:369-77.
21. Redgrave TG, Carlson LA. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridaemic man. J Lipid Res 1979;20:217-29.
22. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglycerides-rich lipoprotein during alimentary lipemia. J Clin Invest 1993;91:748-58.
23. Lopes-Virella MF, Stone P, Ellis S, Colwell JA Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1997;23:882-4.
24. Karpe F, Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 1994;35:1311-7.
25. Keating GM, Ormond D. Micronized fenofibrate: an update review of its clinical efficacy in the management of dyslipidemia. Drugs 2002;62:1909-44.
26. Steals B, Dallongeville J, Aureux J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
27. de Man FH, de Beer F. van der Laarse A., Jansen H., Leuven J.A., Souverijn J.H. et al. The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis 2000;153:363-71.